BioMason, headquartered in United States, remains privately held in the biotechnology space. No public ticker exists for the company.
BioMason has no published valuation.
Biomason is a biotechnology company founded in 2012 and headquartered in the United States that grows cement with microorganisms instead of firing limestone. Its biocement forms calcium carbonate crystals that bind aggregate into concrete, and the company sells precast products such as BioBasedTile through its partnership with FRONT.
Biomason manufactures at the Biobeton factory in Denmark, built with the country's largest precast concrete producer, IBF, which was qualified for production in 2023.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds BioMason.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. BioMason availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — BioMason included.
The routes section explains what is realistically available for a company at this stage.
No. BioMason is a private company; its shares do not trade on a public exchange.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
